Diality Inc., a medical device company headquartered in Irvine, Calif., announced the appointment of Ravi Parthasarathy as Chief Technology Officer. In his new role, Parthasarathy will lead the technology development efforts for the Moda-flxTM Hemodialysis System, designed to improve the quality of life for patients with kidney disease.
Parthasarathy brings with him decades of experience in product development team leadership, with his most recent role being Vice President, Device Engineering at ICU Medical. Prior to his tenure at ICU Medical, he held leadership and product development positions at prominent companies such as Baxter Healthcare, Motorola, Siemens Medical Systems, and General Motors.
“We are thrilled to welcome someone of Ravi’s calibre to the Diality team,” said Osman Khawar, M.D., CEO of Diality. “His extensive experience in leading the development of innovative products, combined with his alignment with Diality’s mission, vision, and values, make him the ideal candidate to drive our technology initiatives forward.”
As Diality continues to advance, Clayton Poppe will transition to the role of Chief Scientific Officer (CSO), where he will oversee the company’s research, quality, and regulatory functions.
The Moda-flxTM Hemodialysis System is a patient-inspired solution aimed at empowering healthcare professionals to provide personalised care for patients with kidney disease.
“Diality’s commitment to improving the lives of patients impacted by kidney disease resonates deeply with me,” said Mr. Parthasarathy. “I am excited to contribute to the development of the Moda-flxTM Hemodialysis System and bring more innovation to dialysis care.”
